An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
This paper is a narrative review evaluating bremelanotide (Vyleesi), a melanocortin receptor agonist delivered by injection, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The authors conducted a PubMed literature search of peer-reviewed publications and synthesized available evidence on the drug's proposed mechanism of action, pharmacokinetics, efficacy, and safety profile. The review notes that bremelanotide is thought to work by activating central melanocortin signaling pathways that may enhance sexual desire. Based on clinical trial data, the authors report that bremelanotide produced statistically significant improvements on validated questionnaires measuring sexual desire and distress; however, they characterize the overall clinical benefit as modest. The most commonly reported adverse event across trials was nausea, occurring in approximately 40% of participants. The authors caution that interpreting trial results is complicated by methodological challenges inherent to female sexual dysfunction research, including a pronounced placebo effect, long recall periods, and outcome measures susceptible to expectation bias. This paper does not present original trial data and relies on synthesis of existing literature, limiting its ability to independently confirm efficacy or safety claims.
Why this grade: This is a narrative review synthesizing clinical trial literature rather than an original study, so it provides an overview of existing human evidence but does not independently generate new trial data.
Introduction Female sexual response implies a deep intertwining between psychosocial and neurobiological mediators. Regulation of central melanocortin signaling may enhance sexual desire. In premenopausal women with hypoactive sexual desire disorder (HSDD), melanocortin receptor agonist bremelanotide (Vyleesi) has been hypothesized to trigger excitatory brain pathways. Areas covered Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications on the current evidence on the pharmacotherapy with bremelanotide was performed using the PubMed database. Expert opinion Bremelanotide appears to be moderately safe and well-tolerated; the most common adverse reaction is nausea (40%). Although data from clinical trials demonstrated a significant change in validated questionnaires, the overall clinical benefit appears to be modest. However, these results should be interpreted in the light of the dramatic challenges in conducting well-designed clinical trials for female sexual dysfunction, due to the significant placebo effect of pharmacotherapy, and the frequent use of outcome measures that are likely to be highly susceptible to expectation biases, such as long periods of recall of sexual and emotional response.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.